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ABSTRACT
Background: Folic acid supplementation during pregnancy plays an important role in fetal growth

and development. To our knowledge, no experimental study has examined the effect of folic acid
on fetal brain growth in women who smoke cigarettes during pregnancy.
Objectives: The aim of this study was to investigate the efficacy of higher-dose compared with
standard-dose folic acid supplementation on prenatal fetal brain growth, measured by head
circumference, brain weight, and brain-body weight ratio (BBR).
Design: In this randomly assigned, double-blind, controlled clinical trial, we recruited 345
smoking pregnant women attending a community health center in Tampa, FL between 2010 and
2014. Participants were randomly assigned in a 1:1 ratio to receive either 0.8 mg folic acid/d

(standard of care at the study center) or 4 mg folic acid/d (higher strength). Participants were also
enrolled in a smoking cessation program. A 2-level linear growth model was used to assess
treatment effect and factors that predict intrauterine growth in head circumference over time.
Multiple linear regression analyses were conducted to estimate the effect of higher-strength folic
acid on head circumference at birth, fetal brain weight, and fetal BBRs.
Results: Mothers who received the higher dose of folic acid had infants with a 1.18 mm larger

mean head circumference compared with infants born to mothers who received the standard
dose, but this difference was not statistically significant (P = 0.2762). Higher-dose folic acid also
had no significant effect on brain weight. The BBR of infants of mothers who received
higher-dose folic acid was, however, 0.33 percentage points lower than that for infants of
mothers who received the standard dose of folic acid (P = 0.044).
Conclusions: Infants of smokers in pregnancy may benefit from higher-strength maternal folic acid

supplementation. We noted a decrease in the proportion of infants with impaired BBR among
those on higher-dose folic acid. This trial was registered at clinicaltrials.gov as NCT01248260.
Curr Dev Nutr 2019;3:nzz025.
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The role of maternal smoking on fetal development is well documented (1–3). Nicotine readily
crosses the placenta into the fetal serum and brain, (4) and has been found to be neurotoxic
(5). Maternal tobacco exposure is associated with reduced head circumference (1, 2), altered
indicators of infant body proportionality, such as brain-body weight ratio (BBR) (3), and infant
neurocognitive developmental problems (6, 7). Although smoking cessation before midpregnancy
may mitigate smoking-related deficits in infant head circumference and BBR (2, 3), many mothers
find it difficult to quit, thereby exposing their unborn babies to the harmful effects of tobacco.
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Biomedical Research Program, FL, Department of
Health (grant numbers 4KB03 and 1KG14-33987).
The trial protocol was approved by the Institutional
Review Board of the University of South Florida.
Address correspondence to KKY (e-mail:
kadegoke@adelphi.edu).
Abbreviations used: BBR, brain-body weight ratio;
RBC, red blood cell; SGA, small for gestational age.
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Methods
Trial population and design
This study is a randomized, double-blind, controlled clinical trial
primarily conducted to assess the effect of high-strength folic acid on
fetal body and brain size. Screening took place among 860 pregnant
smokers; 345 met the eligibility criteria and were enrolled in the study.
The eligible participants were randomly assigned in a 1:1 ratio to receive
either 0.8 mg folic acid/d (standard of care at the study site) or 4 mg
folic acid /d (higher-dose treatment). The folic acid tablets had the
same color, shape, size, and were packed in identically coded bottles.
Allocation concealment was achieved through the pharmacy. Based
on the randomization card received from the patient, the pharmacist
gave a bottle that contained either a 0.8 or 4 mg folic acid tablet. The
code on the bottle was the only distinguishable feature which was used
to determine what the bottle contained, and this was concealed with
patient ID labels. The physicians, ultrasound technicians, laboratory
staff, study investigators, and study participants were all blinded to the
treatment groups. Randomization was performed through a computergenerated randomization schedule with the use of a permuted block
design, with a block size of 12. This type of design was chosen to allow
balance in the number of participants in each group at the end of the
clinical trial.
Participants were recruited between 2010 and 2014 at the Genesis
Clinic, Tampa, FL, a community health center affiliated with the
Department of Obstetrics and Gynecology of the University of South
Florida. Women were eligible to participate in the study if they fulfilled
the following criteria: 1) current smokers, 2) aged 18–44 y; 3) at
<21 wk gestation, as confirmed by last menstrual period; and 4)
residents of Tampa, FL, or a surrounding area, to facilitate follow-up

and reduce attrition. To identify pregnant women who smoked at
baseline, screening for cotinine—a biological marker for nicotine—in
saliva was performed. Women with detectable cotinine concentrations
of ≥1 on a NicAlert test strip were confirmed eligible for the study.
Women receiving chronic blood transfusion may have inaccurate
measures of red blood cell (RBC) folate concentrations, due to
transfused RBCs. Additionally, patients treated with anticonvulsants
may have folate deficiency as a side effect of the medication (18).
Participants were therefore excluded if there was evidence of chronic
blood transfusion and generalized seizure disorder treated with anticonvulsant medication.
Fetal ultrasound assessments, study questionnaires, and salivary
cotinine laboratory assessments were completed during the first 3
study visits. Participants were questioned regarding tablet intake and
compliance, and the reported number of tablets consumed was crosschecked by observing the remaining number of tablets in each bottle.
Women who adhered during their second and third visits were
categorized as compliant, whereas those who did not adhere during
≥1 of the visits were grouped as noncompliant. At delivery, cotinine
concentration was further evaluated, and fetal body measurements were
taken. Written informed consent was obtained from all the participating
women before trial-related procedures were initiated. Informed consent
was available in both English and Spanish. Monetary compensation per
clinical visit was estimated based on the median hourly wage for the
community and the travel costs. For the total of 4 visits and completion
of a dietary history questionnaire, a total of US$90 was reimbursed per
participant as follows: first visit US$20; second visit US$20; third visit
US$20; at delivery US$20; and dietary history questionnaire completion
US$10.
Smoking cessation program
All women enrolled in the trial signed a contract stating they agreed
to commit to quitting smoking and attended ≥1 smoking cessation
session at the study site for smoking mothers, or called the Florida
Quitline, a toll-free telephone-based tobacco use cessation service. The
counseling sessions focused on the following: 1) receipt of self-help
materials and how to make a quit attempt; 2) effects of secondhand
smoke, partners who smoke, and tips on how to establish smoke-free
homes and cars; 3) stress management and benefits of not smoking;
and 4) prevention of smoking relapse. Women who persistently tested
positive to salivary cotinine were referred by study personnel to Florida’s
Quitline. Additionally, all women were linked to community smoking
cessation services, such as the Hillsborough County Healthy Start
program, a free, voluntary, and intensive smoking cessation program.
Endpoint measures
The outcomes included prenatal fetal brain growth, defined as 1) rates
of growth in intrauterine ultrasound measure of head circumference
(growth velocity); and 2) 2 different measures of cumulative head circumference growth (fetal brain weight and fetal BBR). Serial ultrasound
measurements of head circumference were obtained during 3 study
visits according to standardized ultrasound procedures. Intrauterine
head circumference was measured to the nearest millimeter on a
transverse view of the fetal head in a plane showing both thalami and
the third ventricle. The second outcome, fetal estimated brain weight,
was derived from the National Institute of Neurological Disorders
CURRENT DEVELOPMENTS IN NUTRITION
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A likely mechanism of action of maternal smoking on adverse fetal
outcomes is through a reduction in the concentration and activity of
maternal folic acid reserve (8, 9). Smokers are more likely to consume
diets deficient in folate and have impaired folate metabolism (9–11).
Low maternal folate concentrations reduce the bioavailability of folate
to the developing fetus, resulting in impaired growth (12). Previous
studies suggest that prenatal folate deficiency might have an adverse
effect on global fetal brain growth (13), and folate supplementation
in early pregnancy may increase head circumference at birth (13) and
prevent neurodevelopmental disorders in offspring (14, 15).
The role of folic acid supplementation and folate concentrations
in fetal head growth among women of reproductive age is also well
documented (13, 16). However, there is a dearth of research on
the effect of folic acid supplementation among high-risk subgroups,
such as women who smoke during pregnancy. To our knowledge,
no experimental study has been conducted to examine this relation.
In this study, we investigate the efficacy of high-strength compared
with standard-dose folic acid on increasing prenatal brain growth.
Study outcomes include head circumference, brain weight, and BBR.
Head circumference is a noninvasive proxy for fetal brain growth and
development (16), and is closely correlated to brain volume (17). We
hypothesize that among mothers who smoke cigarettes in pregnancy,
higher-dose folic acid treatment will be associated with increased fetal
brain growth.

Folic acid intake and fetal brain growth 3

Covariates
Based on prior knowledge, several maternal and infant characteristics were considered as potential confounding factors due to their
demonstrated association with fetal brain development. These include
sociodemographic factors (e.g., maternal age, race, marital status,
and insurance status), lifestyle factors (cotinine concentration, alcohol
consumption, dietary folate, and maternal BMI), perinatal factors (e.g.,
maternal depression, stress, gestational age), and maternal chronic
diseases, such as hypertension and diabetes. Gestational age at delivery,
a measure of duration of the pregnancy in weeks, was based on
dating ultrasound at first prenatal visit and the date of delivery of the
baby.
Sociodemographic and lifestyle factors were extracted from participants’ medical records, specifically the American College of Obstetrics
and Gynecology form. Dietary folate was assessed through the use of
a proxy, maternal red blood cell (RBC) folate concentration at study
baseline. RBC folate was measured by ELISA. This was the preferred
folate biomarker because of its advantages of long-term stability and
reduced susceptibility to sudden changes in diet (22). Depression was
assessed with the use of the Edinburgh Postnatal Depression Scale. The
Edinburgh Postnatal Depression Scale is a validated tool for assessing
antenatal and postnatal depressive symptoms (23). Stress was measured
with the use of the Perceived Stress Scale 14, which is a validated tool
for comparisons between people in study samples (24).
Cotinine was measured by a test of maternal saliva for the presence
of cotinine with NicAlert (Jant Pharmacal Corporation), a rapid
semiquantitative screening test. Salivary cotinine analysis is the most
sensitive and specific of the 3 types of cotinine measures (25).
Statistical analysis
We assessed differences in the baseline sociodemographic, lifestyle, and
health-related characteristics of study participants by treatment group.
Compliance rate between both groups was also examined. Means of
continuous data were compared through the use of independent t tests
or ANOVA, whereas categoric variables were compared with the chisquare test. Based on the intention-to-treat population, birth outcomes
for all study participants were described in terms of frequencies and
percentages. All primary analyses were conducted on a modified
intention-to-treat basis and included participants who completed the
trial with an observed endpoint, irrespective of compliance to protocol.
Based on a power of 80%, a type 1 error rate of 5%, and a 50% reduction
CURRENT DEVELOPMENTS IN NUTRITION

in the rate of loss of fetal brain growth, the estimated sample size
required to detect a difference in the efficacy of high-strength compared
with standard-dose folic acid on enhancing brain development was a
total of 100 participants. Growth potentials for fetuses with congenital
anomalies or those from multiple gestations may not be comparable
to singleton pregnancies without abnormalities. Analyses therefore
excluded all pregnancies that ended in a fetal loss (abortions, fetal
demise, stillbirths, miscarriages), congenital anomalies, or multiple
births.
Because there were 4 repeated measures of cotinine concentration
from participants during the trial, we decided to identify the unique
paths of cotinine concentrations throughout the pregnancy through
the use of a group-based latent class trajectory model. This approach
offers a data-driven method to identify distinct individual patterns of a
variable of interest and the corresponding probability of falling into each
pattern, also known as the posterior probability. Trajectory analyses
were conducted, and participants were then classified based on their
highest posterior probability. All statistical tests were 2-sided, with an
α level set at P < 0.05. We used SAS version 9.4 for all analyses.

Fetal brain growth trajectory
The primary outcome was the rate of intrauterine growth in head
circumference from the beginning of the second trimester of pregnancy
until delivery. A 2-level linear growth model (multilevel model) was
used to assess treatment effect and factors that predict intrauterine
growth in head circumference over time. Multilevel modeling accounts
for the dependency in observations when data have a nested, multilevel
structure. In this study, the level 1 relation between gestational age and
fetal head circumference was modeled individually for each participant,
and the average relation across participants was reported. level 2
variables were then sequentially included in the model to account for
differences between babies in average fetal brain growth. These subjectlevel covariates comprised maternal BMI, cotinine concentrations, and
fetal sex. The primary exposure (treatment arm) was also included.
The level 1 variable, repeated measures of gestational age, was centered
at 13 wk because this period signifies the beginning of the second
trimester of gestation. Furthermore, no ultrasound measurements of
head circumference were recorded before 13 wk gestation.
The treatment effect, i.e., the difference between the 2 groups,
was determined from the multilevel models. In the first model, the
unconditional growth in head circumference was modeled as a function
of gestational age. The intercept and slopes were fit as random effects,
which varied across fetuses. An unstructured covariance matrix had
the best fit and was utilized in modeling. Variables that were either
associated with folic acid folate treatment or head circumference
at birth in our bivariate analysis or the literature were included in
our model. Based on the log-likelihood ratio, only 3 of the likely
confounding variables improved the model fit, namely cotinine group,
sex, and BMI. In addition to the unconditional model (model 1), results
from the following models were also reported: (model 2) model 1 +
treatment; (model 3) model 2 + cotinine group trajectory; (model 4)
model 3 + fetal gender; and (model 5) model 4 + maternal BMI.
Model 5 had the best fit. Thus, the overall treatment effect and other
fixed- and random-effects parameter estimates were reported from
this model.
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and Stroke’s Collaborative Perinatal Project and was calculated from
the formula: [0.037 × head circumference (cm)2.57 ] (19). Head
circumference at birth was measured to the nearest centimeter with a
measuring tape. The third outcome, the BBR, is the proportion of the
body weight that resides in the brain (20, 21). The BBR was calculated as
100× the ratio of the infant’s estimated brain weight to its birth weight
and is expressed as 100 × [0.037 × head circumference (cm)2.57 ]/birth
weight (g). A high BBR indicates a higher percentage of birth weight
residing in the brain, whereas a lower BBR suggests a lower fraction
of birth weight residing in the brain (3). The typical values for healthy
infants are estimated to be 9–10% (17). Furthermore, higher BBR
indicates larger brain weight for a given head circumference and is
associated with small-for-gestational-age (SGA) infants (17).
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Cumulative growth in the fetal brain
We examined the effect of the intervention on fetal brain weight and
fetal BBRs at birth. Multiple linear regression analyses were conducted
separately for the outcomes. To account for potential confounders, we
controlled for race because of the imbalance across treatment groups
after randomization. Cotinine group trajectory was also included in the
model to account for possible changes in cotinine concentrations during
the course of pregnancy. Mean differences in the outcomes and their
corresponding standard errors were reported.
Results
Study participants
Figure 1 describes participant enrollment and follow-up. A total of
345 smoking pregnant women were enrolled in the trial; 171 women

were randomly assigned to the high-dose folic acid group and 174
to the standard-dose folic acid group. Of these women, 258 (74.8%)
had ≥2 ultrasound measurements of head circumference, and 215
(62.3%) had outcome data on head circumference at delivery. These
numbers represent the count of participants included in the modified
intention-to-treat analysis of brain growth trajectory and cumulative
brain growth, respectively.
Sociodemographic, lifestyle, and health-related characteristics of
study participants by treatment arm are shown in Table 1. The baseline
characteristics of the participants in the 2 groups were similar, except for
race. Women of “other” races, including Hispanic women, were more
likely to be assigned to the standard of care. The mean ± SD age of
participants was 26.7 ± 5.6 y. The mean gestational age at enrollment
and the mean baseline folate concentration were 12.3 ± 3.9 wk and
718.5 ± 187.0 ng/mL, respectively. The trial population predominantly
CURRENT DEVELOPMENTS IN NUTRITION
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FIGURE 1 Enrollment, randomization, and follow-up of participants.
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TABLE 1 Baseline sociodemographic, lifestyle, and health-related characteristics of all randomly assigned study participants by
folic acid treatment (n = 345)1

Variable

26.7
12.3
2.9
718.5

±
±
±
±

5.6
3.9
1.4
187.0

26.4
12.4
3.0
731.3

±
±
±
±

5.1
3.9
1.5
180.9

Standard-dose
folic acid
group (n = 174)
27.3
12.2
2.9
706.0

±
±
±
±

5.8
3.9
1.4
192.3

P value2
0.10
0.57
0.35
0.21
0.03∗

148 (42.9)
140 (40.6)
47 (16.5)

78 (45.6)
74 (43.3)
19 (11.4)

70 (40.2)
66 (37.9)
38 (21.8)

34 (9.8)
311 (90.1)

20 (11.7)
151 (88.3)

14 (8.05)
160 (91.9)

21 (6.1)
324 (93.9)

8 (4.7)
163 (95.3)

13 (7.5)
161 (92.5)

328 (95.1)
17 (4.9)

161 (94.1)
10 (5.9)

167 (96.0)
7 (4.0)

111 (32.4)
85 (24.8)
147 (42.9)

53 (31.0)
36 (21.0)
82 (47.9)

58 (33.7)
49 (28.5)
65 (37.7)

0.12

30 (9.5)
287 (90.5)

18 (11.2)
142 (88.7)

12 (7.6)
145 (92.4)

0.27

94 (31.0)
209 (69.0)

50 (32.9)
102 (67.1)

44 (29.1)
107 (70.9)

0.48

191 (55.4)
154 (44.6)

95 (55.6)
76 (44.4)

96 (55.2)
78 (44.8)

0.95

63 (18.3)
282 (81.7)

31 (18.1)
140 (81.9)

32 (18.4)
142 (81.6)

0.95

0.25

0.28
0.43

Values are n or means ± SDs. Some cell numbers do not sum up to 345 due to missing data. ∗ Significant P values. RBC, red blood cell.
NicAlert cotinine test strips display seven levels (0–6), each of which represents a range of salivary cotinine concentrations. Higher levels on the strip indicate a higher
range of cotinine.
1
2

comprised single/divorced women (90.1%) and without insurance or
on public insurance plans (95.1%). Approximately two-thirds of the
population was either overweight or obese (67.7%). There were no
statistical differences in the rate of excluded outcomes due to fetal loss
by treatment group. Compliance rate was also not significantly different
in the higher-dose folic acid group (87.7%) compared with the standard
of care group (92.7%) (P = 0.1741).
Figure 2 illustrates the cotinine trajectories for trial participants.
We discriminated 3 distinct groups of maternal cotinine velocities:
one with a consistently high concentration of cotinine, another with a
low cotinine concentration, and a third group with moderate cotinine
concentration but a marked decline towards the end of gestation.
Almost half of the trial participants (48.3%) belonged to the group with
a consistently low cotinine concentration. At the end of the study, only
3.0% of the women with cotinine data at delivery (n = 8) had stopped
smoking (zero cotinine concentration).
Fetal brain growth trajectory
Table 2 shows the results of multilevel linear growth models for
the longitudinally measured fetal head circumference based on the
CURRENT DEVELOPMENTS IN NUTRITION

modified intention-to-treat population. In the adjusted model, the
mean head circumference at 13 wk (due to centering at 13 wk) for
all fetuses was 109.2 mm (P < 0.001). This time corresponds to the
beginning of the second trimester of pregnancy. The average rate
of growth in head circumference per week starting at the onset of
the second trimester of gestation was 9.66 mm, and this finding was
statistically significant (P < 0.001). Although infants of participants
who received the higher-strength dose of folic acid had a 1.18 mm larger
head circumference than the infants of those who received the standard
folic acid dose, this difference was not statistically significant (P = 0.28).
The interindividual variance in the outcome was 67.7 mm (P < 0.001),
indicating that the initial head circumference at a gestational age
of 13 wk across fetuses was significantly different. This finding was
mainly explained by differences in maternal BMI and fetal sex. The
intraindividual variance was 70.1 mm and was statistically significant
(P < 0.001), indicating significant variability in brain growth over
time across children. Maternal cotinine group concentration accounted
mainly for this difference. The cotinine group trajectory, however, had
no significant effect on the rate of brain growth. Fetuses with a smaller
head circumference at the beginning of the second trimester had a
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Age, y
Gestational age, wk
Baseline cotinine2
Baseline RBC folate, ng/mL
Race
White
Black
Other
Marital status
Married
Single/divorced
Spanish speaking
Yes
No
Insurance
Public/none
Private
BMI
Not overweight (<25.0 kg/m2 )
Overweight (25.0–29.9 kg/m2 )
Obese (≥30.0 kg/m2 )
Alcohol use
Yes
No
Illicit drug use
Yes
No
Stress score
High
Low
Depression score
High
Low

All subjects

High-dose
folic acid
group (n = 171)
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FIGURE 2 Longitudinally derived cotinine trajectories in the
modified intention-to-treat population (n = 319). Each straight line
reflects an individual cotinine trajectory: 1, low level; 2, moderate
level; and 3, high level.

Discussion
Our randomized clinical trial compared the efficacy of a combination
of higher-strength folic acid supplementation versus standard-ofcare folic acid dose on prenatal brain growth among smokers in
pregnancy. Higher-strength folic acid supplementation in combination
with smoking cessation had no effect on intrauterine brain growth from
the beginning of the second trimester of gestation through delivery. We
observed a significant effect of maternal folic acid treatment on BBR, but
no effects on brain weight at birth. The absence of a difference in the rate
of intrauterine brain growth and brain weight at birth by trial arm might
be explained by the initiation period of folic acid supplementation.
The mean gestational age at study enrollment and commencement
of supplementation was 12.3 wk, approximately the end of the first
trimester of pregnancy.
The infants of women on higher-strength folic acid experienced a
0.33 percentage point reduction in BBR compared with their counterparts on the standard treatment (P = 0.04). This finding suggests

faster rate of growth than those with a larger head circumference
(τ 10 = −6.00). Compared with male fetuses, female fetuses had a
3.2 mm slower growth rate in head circumference (P = 0.003).
Cumulative growth of the fetal brain
The mean ± SD head circumference of babies at birth was 33.8 ±
2.0 cm. Table 3 shows multivariable linear regression results of the effect
of folic acid treatment on fetal brain weight at birth. Higher-dose folic
acid had no significant effect on brain weight in our participants (mean
± SE difference: 6.90 ± 5.85 g; P = 0.24). Compared with infants of
mothers in the low-cotinine groups, infants of mothers in the high- or
moderate-cotinine groups had ∼30 g lower brain weight (P < 0.001).

TABLE 2 Multilevel linear growth models for the effect of folic acid treatment on growth in fetal head circumference (n = 258)1
Parameter
Fixed effects
Intercept (γ 00 )
Gestational age2 (γ 01 )
Treatment (γ 10 )
High dose
Standard dose
Group
Low
Moderate
High
Gender
Female
Male
BMI
Not overweight (<25.0 kg/m2 )
Overweight (25.0–29.9 kg/m2 )
Obese (≥30.0 kg/m2 )
Deviance (–2LL)
1

Model 1

Model 2

Estimate
Model 3

Model 4

Model 5

108.16∗
9.70∗

107.72∗
9.70∗

107.67∗
9.70∗

108.19∗
9.69∗

109.20∗
9.66∗

—
—

1.02
—

0.98
—

1.38
—

1.18
—

—
—
—

—
—
—

0.94
1.30
—

0.90
1.73
—

0.78
1.84
—

—
—

—
—

—
—

−3.10∗
—

−3.21∗
—

—
—
—
8188.6

—
—
—
8185.7

—
—
—
8180.4

—
—
—
7775.2

−1.61
−0.75
7736.6

2

Model 1 was used as baseline model for computing the explained individual variance (σ ) in head circumference growth accounted for by folic acid treatment. Model
1 was used as the baseline model for computing the explained intercept variance (τ 00 ) in head circumference growth accounted for by folic acid treatment. ∗ Values are
significant at P < 0.05.
2
Centered variable (centering done with the use of the value at 13 wk).
CURRENT DEVELOPMENTS IN NUTRITION
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Infants of black mothers also had smaller brain weight at birth than
infants of white mothers (P = 0.01).
The fetal BBR for infants of the study participants ranged from
7.4% to 13.9%. The BBR of infants of mothers who received high-dose
folic acid treatment was 0.33 percentage points lower than for infants
of mothers who received the standard dose of folic acid (P = 0.04;
Table 4). Unlike other measures of cumulative brain growth, high
cotinine group and black race were associated with higher BBR.
Compared with women who had low cotinine concentrations, mothers
with high cotinine concentrations had 0.93% higher BBRs (P < 0.001).
Infants of black mothers had ∼0.5% higher BBRs than infants of white
mothers (P = 0.007).
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TABLE 3 Effect of folic acid treatment on fetal brain weight
(g) at birth (n = 215)1
Variable

β ± SE

P value

328.55 ± 10.74

<0.001
0.24

6.90 ± 5.85
Ref.

—

Ref.
−25.81 ± 6.54
−29.56 ± 8.20

<0.001∗
<0.001∗

Ref.
−16.16 ± 6.48
−8.79 ± 9.00

0.01∗
0.33

Values are adjusted for race and cotinine group trajectory. ∗ Values are significant
at P < 0.05. β, estimate; Ref., reference group.

1

that folic acid does not favor the fetal brain over fetal body growth. A
high BBR signifies a larger brain weight for a given head circumference,
and this is commonly observed in SGA infants (17) and infants with
intrauterine growth restriction (25). Therefore, the decrease in BBR
found in this trial correlates with a lower risk of SGA birth among the
higher-dose folic acid arm (26). Harel et al. (27) reported that a higher
BBR was associated with a more severe intrauterine growth restriction
process and a greater risk that the fetal brain would be affected (27).
Our finding has potential clinical implications: it demonstrates that
high-dose folic acid will be beneficial in terms of optimal brain growth
development among infants of smokers.
Significant relations between cotinine trajectory group and the
cumulative measures of brain growth were also observed. A doseresponse relation was observed for all outcomes. Higher cotinine
concentration was associated with worse outcomes, i.e., reduced brain
weight and higher BBR. Lindley et al. (3) found similar effects of
smoking on head circumference and BBR. In their observational study,
nonsmokers were compared with mothers who stopped smoking by
32 wk of gestation, light smokers who continued to smoke, and heavy
smokers who continued to smoke during pregnancy. A dose-response
gradient was observed with these self-reported smoking levels. It is
well documented that maternal smoking affects fetal brain development
and results in neurocognitive issues, such as deficits in intelligence
quotient in the offspring (28, 29). Because infants born to mothers with
lower cotinine concentrations had a reduced risk of suboptimal fetal
brain growth than those born to mothers with higher concentrations,
having women quit smoking will have significant implications for brain
development. It is noteworthy that despite being enrolled in smoking
cessation programs, only 3% of our participants quit smoking. Other
findings in this trial are the increased risk of adverse cumulative brain
growth outcomes among blacks. Our study confirms previous reports
of racial disparities in birth outcomes, with black mothers having worse
birth outcomes, including infants with lower birth weight and smaller
head circumference, than white mothers (30).
Our study has some limitations. We lost a relatively high proportion
of our participants to follow-up. For instance, in our multilevel
modeling, we had data on only 82.7% (n = 258) of the 319 women
eligible to be included in the modified intention-to-treat analysis.
There were no significant differences in demographic characteristics
CURRENT DEVELOPMENTS IN NUTRITION

TABLE 4 Effect of folic acid treatment on fetal BBR at birth
(n = 215)1
Variables
Intercept
Treatment
High dose
Low dose
Cotinine group
Low
Moderate
High
Race
White
Black
Other

β ± SE

P value

10.44 ± 0.30

<0.001
0.04∗

−0.33 ± 0.16
Ref.

—

Ref.
0.21 ± 0.18
0.94 ± 0.23

0.25
<0.001∗

Ref.
0.49 ± 0.18
0.30 ± 0.25

0.007∗
0.23

Values are adjusted for race and cotinine group trajectory. ∗ Values are significant
at P < 0.05. β, estimate; BBR, brain-body weight ratio; Ref., reference group.

1
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Intercept
Treatment
High dose
Standard dose
Cotinine group
Low
Moderate
High
Race
White
Black
Other

between the participants lost to follow-up and those who remained in
the study. Therefore, we do not expect loss to follow-up to bias our
results. We did not directly assess or control for the effect of diet, a
possible confounder in this study. However, there is a reduced likelihood
of dietary differences by treatment arms because of randomization.
Further, the baseline comparison of RBC folate, a proxy for longterm folate diet, supports this claim. As with most clinical trials, the
generalizability of our findings may be an issue. Voluntary participants
in studies can be different from nonparticipants. Our study sample
also included low-income women with a high proportion of minorities,
further limiting the generalizability of our findings. On the other hand,
this is a study strength because minority populations are understudied
in clinical trials. Therefore, our result can enrich the literature on the
effect of folic acid in minorities.
Another strength of our study is the use of a double-blind,
randomized clinical trial, which allows for causal inference. We also
conducted modified intention-to-treat analysis, and therefore our
findings likely closely represent the effectiveness of higher-strength folic
acid in improving prenatal brain growth under real-world conditions.
To our knowledge, this is the first randomized controlled trial to
report on the efficacy of high-strength folic acid in combination with
enrollment in a smoking cessation program in preventing adverse fetal
brain outcomes among smokers in pregnancy.
The vulnerability of the developing fetal brain is dependent on
whether an exposure or its active metabolites reach the developing
nervous system and the period of exposure (29). In our trial, we cannot
say with certainty that folic acid supplementation was commenced at
the critical period of brain growth, and that folic acid reached the brain
at the dose at which we supplemented. Future experimental studies
should investigate the role of early folic acid supplementation among
smokers, starting from before conception until delivery. Doing so may
help in identification of the critical period of development associated
with maximum folate-associated brain growth. It is also crucial to
understand how folic acid supplementation relates to blood folate
concentrations in the fetal brain. Blood folate concentrations, including
RBC and serum folate, are better proxies for the assessment of folate
status (31). These biomarkers are recommended for assessing folate
bioavailability for optimal growth and development of neural cells.
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In conclusion, we demonstrated a reduction in BBR with the use
of higher-strength folic acid initiated during early-mid pregnancy.
However, no treatment effects were found on intrauterine brain growth
rate and brain weight. Our findings show that smokers in pregnancy
may benefit from folate supplementation in reducing the risk of having
infants with impaired brain-body proportionality.
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